Skip to search formSkip to main contentSkip to account menu

meropenem

Known as: 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-, meropenem [Chemical/Ingredient], 3-(5-dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid 
A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative… 
National Institutes of Health

Related topics

Related topics

30 relations

Broader (2)

Anti-Bacterial AgentsThienamycins
AppendicitisBacterial InfectionsBacteroides InfectionsCarbapenems

Narrower (6)

Meropenem HydrateMeropenem trihydrateMerremPenem

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.
OBJECTIVES The goal of the present study was to obtain a comprehensive overview of the bacteriostatic and bactericidal effects of… 
2008
2008
Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case-control study in intensive care units.
Highly Cited
2007
Highly Cited
2007
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.
Highly Cited
2005
Highly Cited
2005
Pharmacodynamic Evaluation of Extending the Administration Time of Meropenem using a Monte Carlo Simulation
ABSTRACT A Monte Carlo simulation demonstrated that 1 g of meropenem (MEM) every 8 h (q8h) (3-h infusion) has a higher target… 
2005
2005
Class 2 Integron with a Novel Cassette Array in a Burkholderia cenocepacia Isolate
Burkholderia cepacia complex (BCC) organisms are gram-negative opportunistic emerging pathogens associated with a poor prognosis… 
Highly Cited
2003
Highly Cited
2003
Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY…
Highly Cited
2001
Highly Cited
2001
MYSTIC program: summary of European data from 1997 to 2000.
Review
2000
Review
2000
Cephalosporins, carbapenems, and monobactams.
Review
2000
Review
2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) is a global, multicentre surveillance study that… 
Highly Cited
2000
Highly Cited
2000
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure.
Meropenem elimination was studied in six patients with acute renal failure on continuous venovenous haemofiltration (CVVH) or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)